Drug Profile
EC 1456
Alternative Names: EC-1456; Folate-targeted tubulysin - Endocyte; Folate-tubulysin; Folic acid-tubulysin conjugate (EC1456) - EndocyteLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Endocyte
- Class Antineoplastics; Biological toxins; Drug conjugates; Folic acids; Peptides; Small molecules
- Mechanism of Action Folate receptor 1 antagonists; Mitosis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Ovarian-cancer(Late-stage disease) in Canada (IV, Injection)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Ovarian-cancer(Late-stage disease) in USA (IV, Injection)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Second-line therapy or greater) in USA (Parenteral)